1-hydroxy-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid | 103986-80-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-hydroxy-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
• CAS: 103986-80-7
• 化学式: C₁₁H₁₂O₃
• 分子量: 192.214
• InChiKey: NLVBCDOAWYJCLV-UHFFFAOYSA-N

物化性质

• 熔点：
  156-158 °C(Solv: water (7732-18-5); ethanol (64-17-5))
• 沸点：
  355.6±42.0 °C(Predicted)
• 密度：
  1.305±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  1-hydroxy-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid 在 乙醇 、 硫酸 、 一水合肼 作用下， 生成 1-hydroxy-5,6,7,8-tetrahydro-[2]naphthoic acid isopropylidenehydrazide
  参考文献：
  名称：

  Schroeter, Justus Liebigs Annalen der Chemie, 1922, vol. 426, p. 132

  摘要：

  DOI：
• 作为产物：
  描述：

  1-羟基-2-萘甲酸 在 chloro(1,5-cyclooctadiene)rhodium(I) dimer 作用下， 以 甲醇 为溶剂， 反应 12.0h， 以72%的产率得到1-hydroxy-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
  参考文献：
  名称：

  在甲醇中使用氢硅烷对萘酚进行区域选择性和化学选择性还原：5,6,7,8-四氢萘酚核的合成

  摘要：

  描述了一种区域选择性和化学选择性方法，用于通过还原萘酚催化合成生物学上令人感兴趣的5,6,7,8-四氢萘酚。使用甲醇中的氢硅烷可选择性地还原萘酚中的侧链芳香烃，从而使功能性酚骨架保持完整。它提供了一个罕见的示例，该示例使用低成本且空气稳定的氢化硅烷在温和条件下催化还原未活化的芳烃。该反应是可扩展的，并且以高选择性进行，而没有形成1,2,3,4-四氢萘酚副产物，其可耐受敏感的官能团，例如溴化物，氯化物，氟化物，酮，酯和酰胺。

  DOI：

  10.1021/acs.orglett.8b01273

文献信息

• Carboxylation of Phenols with CO₂at Atmospheric Pressure
  作者：Junfei Luo、Sara Preciado、Pan Xie、Igor Larrosa

  DOI：10.1002/chem.201601114

  日期：2016.5.10

  A convenient and efficient method for the ortho‐carboxylation of phenols under atmospheric CO2 pressure has been developed. This method provides an alternative to the previously reported Kolbe–Schmitt method, which requires very high pressures of CO2. The addition of a trisubstituted phenol has proved essential for the successful carboxylation of phenols with CO2 at standard atmospheric pressure, allowing

  已经开发了一种在大气CO 2压力下使酚进行邻羧基羧化的便捷有效方法。该方法提供了以前报道的Kolbe-Schmitt方法的替代方法，后者需要非常高的CO 2压力。已证明添加三取代的苯酚对于在标准大气压下成功地将苯酚与CO 2羧化至关重要，从而可以有效制备各种水杨酸。
• [EN] AMIDE DERIVATIVES AS SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS<br/>[FR] DERIVES D'AMIDE EN TANT QU'INHIBITEURS SELECTIFS DU RECAPTAGE DE LA SEROTONINE
  申请人：PFIZER LTD

  公开号：WO2004111003A1

  公开（公告）日：2004-12-23

  The present invention relates to compounds of formula (I), wherein R1 is selected from: (a) (C1-C6)alkyl, optionally substituted by 1-3 substituents, each independently selected from: (i) CF3, OH, (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkoxy and halo; (ii) Phenyl, optionally fused with phenyl or cyclohexyl, said phenyl or fused phenyl optionally substituted with 1-3 groups selected from (C1-C6)alkyl, (C1-C6)alkyl ester, OH and halo; and (b) (C3-C6)cycloalkyl, optionally fused with (C5-C7)cycloalkyl, said cycloalkyl or fused cycloalkyl optionally substituted by OH, (C1-C6)alkyl, (C1-C6)alkoxy and halo. R2 is Phenyl, optionally fused to (C4-C6)cycloalkyl, phenyl or pyridyl, said phenyl or fused phenyl moiety optionally substituted with 1-3 groups each independently selected from (C1-C6)alkyl, (C1-C6)alkoxy, halo and OH. n is 1 to 2 and pharmaceutically acceptable salts, solvates or polymorphs thereof; With the proviso that when n is 2 and R1 is 2-(3,4-dimethoxylphenyl)-1-ethyl, 3,3­diphemyl-1-propyl or 2,4-difluorophenyl, then R2 cannot be 4-trifluoromethoxyphenyl, 2,4,6-trimethoxyphenyl, 4-acetoxyphenyl or 2,4-difluorophenyl; which are a class of selective serotonin re-uptake inhibitors (SSRIs).

  本发明涉及式(I)的化合物，其中R1从以下选项中选择：(a) (C1-C6)烷基，可选地被1-3个取代基取代，每个取代基独立地从以下选项中选择：(i) CF3，OH，(C1-C6)烷基，(C3-C6)环烷基，(C1-C6)烷氧基和卤素；(ii) 苯基，可选地与苯基或环己基融合，所述苯基或融合苯基可选地被1-3个取代基取代，所述取代基独立地从(C1-C6)烷基，(C1-C6)烷基酯，OH和卤素中选择；和(b) (C3-C6)环烷基，可选地与(C5-C7)环烷基融合，所述环烷基或融合环烷基可选地被OH，(C1-C6)烷基，(C1-C6)烷氧基和卤素取代。R2为苯基，可选地融合到(C4-C6)环烷基，苯基或吡啶基，所述苯基或融合苯基基团可选地被1-3个取代基取代，每个取代基独立地从(C1-C6)烷基，(C1-C6)烷氧基，卤素和OH中选择。n为1至2，以及其药学上可接受的盐、溶剂化合物或多形体；但是当n为2且R1为2-(3,4-二甲氧基苯基)-1-乙基，3,3-二苯基-1-丙基或2,4-二氟苯基时，R2不能为4-三氟甲氧基苯基，2,4,6-三甲氧基苯基，4-乙酰氧基苯基或2,4-二氟苯基；这些是一类选择性5-羟色胺再摄取抑制剂（SSRIs）。
• [EN] AMINO-PYRIDINE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS<br/>[FR] INHIBITEURS DE TYROSINE KINASE SPLÉNIQUE CONTENANT UNE AMINOPYRIDINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2012151137A1

  公开（公告）日：2012-11-08

  The invention provides certain amino-pyridine-containing compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and n are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.

  该发明提供了具有以下化学式(I)的某些含氨基吡啶的化合物或其药用盐，其中R1、R2、R3、R4、R5、R6、R7、R8、R9和n的定义如本文所述。该发明还提供了包括这些化合物的药物组合物，以及利用这些化合物治疗由脾酪氨酸激酶（Syk）激酶介导的疾病或病况的方法。
• Amide derivatives as selective serotonin re-uptake inhibitors
  申请人：Andrews David Mark

  公开号：US20050014789A1

  公开（公告）日：2005-01-20

  The present invention relates to compounds of formula (I), wherein R 1 is selected from: (a) (C 1 -C 6 )alkyl, optionally substituted by 1-3 substituents, each independently selected from: (i) CF 3 , OH, (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 1 -C 6 )alkoxy and halo. (ii) Phenyl, optionally fused with phenyl or cyclohexyl, said phenyl or fused phenyl optionally substituted with 1-3 groups selected from (C 1 -C 6 )alkyl, (C 1 -C 6 )alkyl ester, OH and halo; and (b) (C 3 -C 6 )cycloalkyl, optionally fused with (C 5 -C 7 )cycloalkyl, said cycloalkyl or fused cycloalkyl optionally substituted by OH, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy and halo. R 2 is Phenyl, optionally fused to (C 4 -C 6 )cycloalkyl, phenyl or pyridyl, said phenyl or fused phenyl moiety optionally substituted with 1-3 groups each independently selected from (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, halo and OH; n is 1 to 2; and pharmaceutically acceptable salts, solvates or polymorphs thereof; With the proviso that when n is 2 and R 1 is 2-(3,4-dimethoxylphenyl)-1-ethyl, 3,3-diphenyl-1-propyl or 2,4-difluorophenyl, then R 2 cannot be 4-trifluoromethoxyphenyl, 2,4,6-trimethoxyphenyl, 4-acetoxyphenyl or 2,4-difluorophenyl; which are a class of selective serotonin re-uptake inhibitors (SSRIs).

  本发明涉及式（I）的化合物，其中R1选自：（a）（C1-C6）烷基，可选地被1-3个取代基取代，每个取代基独立地选自：（i）CF3，OH，（C1-C6）烷基，（C3-C6）环烷基，（C1-C6）烷氧基和卤素；（ii）苯基，可选地与苯基或环己基融合，所述苯基或融合苯基可选地被1-3个选自（C1-C6）烷基，（C1-C6）烷酯，OH和卤素的基团取代；和（b）（C3-C6）环烷基，可选地与（C5-C7）环烷基融合，所述环烷基或融合环烷基可选地被OH，（C1-C6）烷基，（C1-C6）烷氧基和卤素取代。R2为苯基，可选地融合到（C4-C6）环烷基、苯基或吡啶基上，所述苯基或融合苯基基团可选地被1-3个独立选自（C1-C6）烷基，（C1-C6）烷氧基，卤素和OH的基团取代；n为1到2；以及其药学上可接受的盐、溶剂或多型性；但当n为2且R1为2-(3,4-二甲氧基苯基)-1-乙基、3,3-二苯基-1-丙基或2,4-二氟苯基时，则R2不能是4-三氟甲氧基苯基、2,4,6-三甲氧基苯基、4-乙酰氧基苯基或2,4-二氟苯基；这是一类选择性5-羟色胺再摄取抑制剂（SSRI）。
• Dna-pk inhibitors
  申请人：——

  公开号：US20040192687A1

  公开（公告）日：2004-09-30

  The invention relates to the use of compounds of formula (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, in the preparation of a medicament for inhibiting the activity of DNA-PK, wherein R 1 and R 2 are independently hydrogen, an optionally substituted C 1-7 alkyl group, C 3-20 heterocyclyl group, or C 5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; X and Y are selected from CR 4 and O, O and CR′ 4 and NR″ 4 and N, where the unsaturation is in the appropriate place in the ring, and where one of R 3 and R 4 or R′ 4 is an optionally substituted C 3-20 heteroaryl or C 5-20 aryl group, and the other of R 3 and R 4 or R′ 4 is H, or R 3 and R 4 or R″ 4 together are —A—B—, which collectively represent a fused optionally substituted aromatic ring. The compounds also selectively inhibit the activity of DNA-PK compared to PI 3-kinase and/or ATM. 1

  本发明涉及使用式(I)化合物及其异构体、盐、溶剂合物、化学保护形式及其前药，在制备抑制DNA-PK活性的药物方面使用。其中，R1和R2分别为氢、可选取代的C1-7烷基、C3-20杂环基或C5-20芳基，或者与它们连接的氮原子一起形成含有4到8个环原子的可选取代杂环环；X和Y从CR4和O、O和CR'4以及NR"4和N中选择，其中不饱和度在环中适当位置，且R3和R4或R'4中的一个为可选取代的C3-20杂芳基或C5-20芳基，而另一个为氢，或者R3和R4或R"4一起为-A-B-，它们共同表示一个融合的可选取代芳香环。这些化合物与PI 3-激酶和/或ATM相比，也具有选择性抑制DNA-PK活性的作用。